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OBJECTIVE—Blockade of angiotensin (Ang) II has been shown
to prevent new-onset type 2 diabetes. We focused on the effects
of AngII on muscle mitochondria, especially on their biogenesis,
as an underlining mechanism of type 2 diabetes.
RESEARCH DESIGN AND METHODS—C2C12 cells and
C57bl/6 mice were used to examine roles for AngII in the
regulation of muscle mitochondria and to explore whether the
effect was mediated by type 1 AngII receptor (AT1R) or type 2
receptor (AT2R).
RESULTS—C2C12 cells treated with 10
8–10
6 mol/l AngII
reduced the mitochondrial content associated with downregula-
tion of the genes involved in mitochondrial biogenesis. The
action of AngII was diminished by blockade of AT2R but not
AT1R, whereas overexpression of AT2R augmented the effect.
AngII increased mitochondrial ROS and decreased mitochondrial
membrane potential, and these effects of AngII were signiﬁcantly
suppressed by blockade of either AT1R or AT2R. Chronic AngII
infusion in mice also reduced muscle mitochondrial content in
association with increased intramuscular triglyceride and dete-
riorated glycemic control. The AngII-induced reduction in mus-
cle mitochondria in mice was partially, but signiﬁcantly, reversed
by blockade of either AT1R or AT2R, associated with increased
fat oxidation, decreased muscle triglyceride, and improved glu-
cose tolerance. Genes involved in mitochondrial biogenesis were
decreased via AT2R but not AT1R under these in vivo conditions.
CONCLUSIONS—Taken together, these ﬁndings imply the
novel roles for AngII in the regulation of muscle mitochondria
and lipid metabolism. AngII reduces mitochondrial content pos-
sibly through AT1R-dependent augmentation of their degradation
and AT2R-dependent direct suppression of their biogenesis.
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R
ecent studies have shown that mitochondrial
content and function are signiﬁcantly reduced in
the skeletal muscle of patients with type 2
diabetes (1,2). Percutaneous biopsy of vastus
lateralis muscle has revealed that subsarcolemmal mito-
chondria, which are believed to be crucial for glucose
transport and fatty acid oxidation, were decreased in type
2 diabetic patients, compared with body weight–matched
nondiabetic patients (2). Moreover, reduced mitochondrial
content and function in muscle have been also observed in
pre-diabetic subjects with a family history of type 2
diabetes (3). Recent microarray analyses have revealed
that expression of genes involved in mitochondrial biogen-
esis and oxidative phosphorylation is coordinately de-
creased in the skeletal muscle of patients with type 2
diabetes (4,5), for example, peroxisome proliferator–acti-
vator receptor  co-activator 1 (PGC1), a representative
transcriptional cofactor for the determination of mito-
chondrial content and function, and nuclear respiratory
factor 1 (NRF1). Furthermore, it has been demonstrated
that mitochondrial function evaluated by the rate of ATP
synthesis is diminished in the skeletal muscle of diabetic
patients and family history–positive pre-diabetic patients
(6,7). These ﬁndings imply that reduced mitochondrial
content in the skeletal muscle is likely to contribute to the
development of insulin resistance and type 2 diabetes
(8,9).
Angiotensin (Ang) II, which is composed of eight amino
acids, is one of the most important molecules in the
renin-angiotensin system. It provokes sodium reabsorp-
tion, vasoconstriction, and elevation of blood pressure and
also plays a critical role in the physiological regulation of
electrolytes and water homeostasis. However, an excess
of AngII may lead to tissue damage, such as atherosclero-
sis, cardiomegaly, and heart and renal failure. AngII is
known to exert its biological effects via two functional
receptors, type 1 and type 2 angiotensin II receptors
(AT1R and AT2R, respectively). To date, most of the
known cardiovascular effects of AngII are believed to be
attributable to AT1R (10). Recent large-scale clinical trials,
including HOPE (Heart Outcomes Prevention Evaluation),
LIFE (Losartan Intervention for Endpoint), CHARM (Can-
desartan in Heart Failure—Assessment of Mortality and
Morbidity), and VALUE (Valsartan Antihypertensive Long-
term Use Evaluation), have demonstrated that ACE inhib-
itors or angiotensin II receptor blockers (ARB) prevent
new onset of type 2 diabetes via their ability to attenuate
AngII signaling (11). As a result of these ﬁndings, the
signiﬁcance of AngII for the development of insulin resis-
tance and regulation of energy metabolism has been
attracting considerable attention (12–14).
It has been demonstrated that AngII provokes insulin
resistance in the skeletal muscle through multiple mecha-
nisms. AngII treatment was found to augment reactive
oxygen species (ROS) production by stimulating NADPH
oxidase in cultured skeletal muscle cells, thus activating
multiple redox-sensitive signaling including nuclear fac-
tor-B (NF-B) and increasing proinﬂammatory cytokines
such as tumor necrosis factor- (TNF-), which impair
insulin action (15,16). Inhibition of insulin signaling by
AngII at multiple levels including insulin receptor, insulin
receptor substrate 1, and phosphatidylinositol 3-kinase
has been demonstrated in aortic smooth muscle cells (17).
Stimulation of primary cultured human preadipocytes by
AngII was found to inhibit differentiation to mature adipo-
cytes, suggesting that the effect of AngII on adipose tissue
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710 DIABETES, VOL. 58, MARCH 2009may inﬂuence glycemic control (18). Furthermore, AngII is
known to affect other hormones that are related to the
regulation of blood pressure, for example, by promoting
the release of aldosterone and vasopressin. It has been
suggested that changes in catecholamine production by
genetic disruption of AT1R in mice may affect glycemic
control (19). Diminished tissue perfusion and lowered
blood potassium concentration caused by AngII may also
be involved in the development of insulin resistance.
These ﬁndings indicate that various mechanisms are likely
to be involved in AngII-induced insulin resistance. How-
ever, the effect of AngII on muscle mitochondrial content
and subsequent inﬂuence on glycemic control has not yet
been elucidated.
In a previous study, we showed that cGMP was involved
in the regulation of mitochondrial content and function of
cultured C2C12 myotubular cells by altering the expres-
sions of the genes related to mitochondrial biogenesis and
the antioxidant system (20). Interestingly, cGMP is an
intracellular second messenger of the vasodilating sub-
stances, natriuretic peptides and nitric oxide, both of
which exert antagonistic effects to AngII actions. In the
current study, we therefore focused on the effects of AngII
on muscle mitochondria, especially on the regulation of
their biogenesis, and their relationship with the pathogen-
esis of glucose intolerance.
RESEARCH DESIGN AND METHODS
Cell culture. C2C12 cells (RIKEN BioResource Center, Tsukuba, Japan) were
grown in a low-glucose (100 mg/dl) medium, as described previously (20).
Cells were fully differentiated, grown to overconﬂuence, and treated in a
24-well dish with or without 10
6–10
8 mol/l AngII (Sigma, St. Louis, MO); an
AT1R blocker, RNH6270 (Olmesartan, 10
5 mol/l, a gift from Daiichi-Sankyo,
Tokyo, Japan); or an AT2R blocker, PD123319 (10
5 mol/l; Sigma). Unless
indicated otherwise, total DNA, RNA, and proteins were extracted from the
cells after 48 h of treatment.
Transient overexpression of angiotensin receptors in vitro and RNA
interference. We constructed angiotensin receptor overexpressing vectors
by fusing the chicken -actin promoter-driven vector, pCAGGS (21) (a gift
from Dr. J. Miyazaki, Osaka University, Japan) with cDNA of mouse AT1R
(GenBank accession no. NM_177322) or AT2R (NM_007429). C2C12 cells were
transiently transfected with these vectors (0.1 g/well) using the Lipo-
fectamine LTX Reagent (Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. We then generated small interfering RNAs (siRNAs) for
genetic blockade of AT1R and AT2R. C2C12 cells were transfected with these
siRNAs, or scrambled RNA as negative control (Stealth RNAi Negative
Control, Invitrogen), by means of a Lipofectamine RNAi Max Reagent (Invitro-
gen) according to the manufacturer’s instructions.
Quantiﬁcation of mitochondrial DNA copy number and gene expres-
sions by real-time PCR. Quantitative PCR analysis was performed by
standard methods. Details of the methods used are provided in the supple-
mental materials (available in an online-only appendix at (http://diabetes.
diabetesjournals.org/cgi/content/full/db08-0949.
Quantiﬁcation of mitochondrial mass, ROS production, and membrane
potential and ATP content. Mitochondrial mass, mitochondrial ROS pro-
duction, and membrane potential of the C2C12 cells were determined,
respectively, with the aid of the ﬂuorescent dyes: MitoTracker Green FM,
MitoSOX Red, and JC-1 (Molecular Probes, Eugene, OR), following the same
procedures as described previously (20). The ﬂuorescent intensity was
estimated by a multi-plate reader (Wallac ARVO SX; Perkin Elmer, Wellesley,
MA). ATP content of the cells was determined with the chemiluminescence
method (ATP bioluminescence Assay Kit HS II; Roche Diagnostics, Basel,
Switzerland). For microscopic analysis, C2C12 cells were stained with the
ﬂuorescent probes and observed with a confocal microscope (LSM 510; Carl
Zeiss, Oberkochen, Germany).
Quantiﬁcation of protein levels by Western blotting. Western blotting
was performed by standard methods. Details of the methods used are
provided in the supplemental materials.
Animal experiments. All animal experiments were performed in accordance
with the animal care and use guidelines of Keio University. Male C57bl/6 mice
(Nihon Clea, Tokyo, Japan) were maintained under speciﬁc pathogen-free
conditions, and exogenous AngII was infused at a dose of 0.1 g/g body
wt/day, which is recognized as a subpressor dose that does not inﬂuence
blood pressure (22). The infusion was carried out via an osmotic mini-pump
(Alzet model 1002; Durect, Cupertino, CA) subcutaneously implanted when
the mice were 8 weeks old. The AngII-infused mice were treated with or
without the AT1R blocker CS-866 (Olmesartan medoxomil, a precursor of
olmesartan with a longer effect in vivo than olmesartan, and a gift from
Daiichi-Sanko) or the AT2R blocker PD-123319, four times per week by oral
administration (10 mg/kg body wt) with a stomach sonde. On day 10, the mice
were killed for tissue harvest.
Glucose tolerance test, indirect calorimetry, and quantiﬁcation of
serum insulin concentration, muscle triglyceride, and enzyme activity
of mitochondria. For the glucose tolerance test, the mice were fasted for 8 h
and intraperitoneally injected with glucose at 2.0 g/kg body weight. Blood
samples were collected from the tail vein, and the blood glucose level was
promptly determined with the glucose dehydrogenase method (ACCU-CHEK
Aviva, Roche Diagnostics). Oxygen consumption and fat oxidation in mice
were determined by means of indirect calorimetry, which was performed for
24 h from 2000 until the next day (ARCO-2000; Arco Systems, Kashiwa, Japan).
Serum insulin concentration was determined with an enzyme-linked immu-
nosorbent assay kit (Ultra-Sensitive Mouse Insulin ELISA kit, 200716; Mori-
naga, Yokohama, Japan). Lipids in quadriceps were extracted with the Folch
method (23), and the triglyceride level was determined with a commercially
available kit (Triglyceride E-test; Wako, Osaka, Japan). We performed Oil-
red-O staining of the muscle, and the method is provided in the supplemental
materials. Enzyme activity of the mitochondrial proteins, cytochrome C
oxidase (COX) and -hydroxyacyl-CoA dehydrogenase (-HAD), was deter-
mined in the skeletal muscle by a commercially available assay kit (Mitochon-
dria Activity Assay Kit, Bio Chain, Hayward, CA) and a standard method (24),
respectively.
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FIG. 1. AngII reduces mitochondrial content in association with an
increase in mitochondrial ROS production in C2C12 cells. C2C12 cells
were incubated with or without AngII (at the concentrations indicated:
10
8 or 10
6 mol/l) for 48 or 96 h. A: Mitochondrial DNA copy number
(mtDNA) estimated by quantitative PCR analysis (n  12 per group).
B: Mitochondrial density (Mt), mitochondrial ROS production
(mtROS), and mitochondrial membrane potential (mtMP) estimated
with the aid of ﬂuorescent probes (n  12). C: ATP content determined
with the chemiluminescence method (n  12). The values were stan-
dardized to those for the control (no AngII treatment). *P < 0.05,
**P < 0.01 vs. control.
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infused mice was performed. Details of the methods used are provided in the
supplemental materials.
Statistical analysis. Statistical analysis was performed by standard meth-
ods. Details of the methods used are provided in the supplemental materials.
RESULTS
AngII reduces mitochondrial content in association
with increased mitochondrial ROS production and
lowers mitochondrial membrane potential in C2C12
cells. To investigate the effect of AngII on mitochondrial
content, ROS production, membrane potential, and ATP
production, we treated C2C12 myotubular cells with or
without 10
8–10
6 mol/l AngII for 48–96 h. Mitochondrial
DNA copy number, which is considered to be a surrogate
marker of mitochondrial content, showed a dose-depen-
dent reduction (22% reduction at 10
6 mol/l, n  12, P 
0.01, Fig. 1A) in the AngII-treated groups. The magnitude
of reduction was similar for 48 and 96 h of incubation with
AngII. Mitochondrial mass, estimated by means of ﬂuores-
cent staining, also decreased as a result of AngII treatment
(9% reduction at 10
6 mol/l, Fig. 1B), in association with a
signiﬁcant increase in mitochondrial ROS (mtROS) (27%
increase, Fig. 1B). Mitochondrial membrane potential
(mtMP) was lowered (6% decrease, Fig. 1B) by AngII,
whereas cellular ATP content was not signiﬁcantly
changed (Fig. 1C).
Blockade of AT2R but not AT1R reverses mitochon-
drial reduction in C2C12 cells caused by AngII,
whereas blockade of either AT1R or AT2R sup-
presses AngII-induced changes in mtROS and mtMP.
To determine the receptor responsible for the effects of
AngII on mitochondria, C2C12 cells were subjected to
pharmacological and genetic blockade of their receptors.
Pharmacological blockade of AngII by the AT1R blocker
RNH-6270 (10
5 mol/l) or AT2R blocker PD-123319 (10
5
mol/l) revealed that the decline in mitochondrial content
was completely reversed by blockade of AT2R (Fig. 2A
and B). Consistent results were obtained by genetic block-
ade of these receptors by siRNA in that the silencing of
AT2R completely reversed the decrease in mitochondrial
content, whereas that of AT1R did not affect it (Fig. 2A).
We conﬁrmed that the siRNAs achieved 	80% reduction in
the expression and protein levels of the receptors by using
quantitative PCR and Western blotting (data not shown).
On the other hand, the increase in mtROS and the decrease
in mtMP induced by AngII were partially, but signiﬁcantly,
suppressed by blockade of either AT1R or AT2R (Fig. 2B).
Using a confocal microscope, we were able to conﬁrm that
the ﬂuorescent probes were distributed speciﬁcally in
mitochondria (Fig. 2C).
We also examined the expressions of genes involved in
mitochondrial biogenesis (PGC1, NRF1, and mitochon-
drial transcription factor A [Tfam]) and found that both
PGC1 and Tfam were decreased in the AngII-treated
group (18% and 16% decrease, respectively, n  12, P 
0.01, Fig. 2D); however, expression of NRF1 was not
affected by AngII. Consistent with its effects on mitochon-
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FIG. 2. Pharmacological blockade or targeted silencing of AT2R but not
AT1R in C2C12 cells recovers mitochondrial biogenesis reduced by
AngII. The AT1R blocker, RNH-6270 (RNH, 10
5 mol/l), or the AT2R
blocker, PD-123319 (PD, 10
5 mol/l), was added to C2C12 cells previ-
ous to the treatment with AngII (10
6 mol/l) for 48 h (A–D). Targeted
disruption of AT1R (1Ri) or AT2R (2Ri) by small interfering RNA
(siRNA) was also performed (A). A: Mitochondrial DNA copy number
(mtDNA) estimated by quantitative PCR analysis (n  12 per group).
B: Mitochondrial density (Mt), mitochondrial ROS production
(mtROS), and mitochondrial membrane potential (mtMP) estimated
with the aid of ﬂuorescent probes (n  12). C: Microscopic analysis of
the cells. C2C12 cells were stained with MitoTracker Green (green, a
probe for mitochondria) or MitoSOX Red (red, a probe for mitochon-
dria-derived ROS) and observed with a confocal microscope. Scale bar:
100 m. D: Expression of genes involved in mitochondrial biogenesis
(n  12). The values were standardized to those for the control. *P <
0.05, **P < 0.01 vs. control. #P < 0.05, ##P < 0.01 vs. the AngII-treated
group. (Please see http://diabetes.diabetesjournals.org/cgi/content/
full/db08-0949 for a high-quality digital representation of this ﬁgure.)
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123319 completely reversed the AII-induced decrease in
PGC1 and Tfam, but AT1R blockade by RNH-6270 did not
affect their expressions (Fig. 2D).
These results indicate that, under the present experi-
mental condition using C2C12 cells, AT1R-dependent sig-
nal pathways have effects on mtROS and mtMP without
any change in mitochondrial content, whereas AT2R-
dependent pathways inﬂuence mitochondrial biogenesis,
mtROS, and mtMP. The expression levels of the receptors
can thus be expected to determine the effect of AngII on
mitochondria.
Overexpression of AT2R in C2C12 cells augments An-
gII-induced reduction in mitochondrial biogenesis.
Next, we performed overexpression of the receptors by
using the CAG promoter–driven expression vectors in
C2C12 cells (Fig. 3A–D). In the AT1R overexpression
group, mtDNA was not signiﬁcantly changed as a result of
treatment with AngII (Fig. 3A); however, in the AT2R
overexpression group, mtDNA showed a major decrease
as the result of treatment with AngII (44% decrease, n 
12, P  0.01, Fig. 3B). Western blot analysis conﬁrmed that
PGC1 and Tfam protein levels in the AT2R overexpres-
sion group were signiﬁcantly diminished by AngII (Fig. 3C
and D). These results were also compatible with those for
their gene expressions under pharmacological blockades
(Fig. 2D).
Exogenous administration of AngII in mice for 1
week provokes glucose intolerance without changes
in body weight or food intake. To explore the effects of
AngII on muscle mitochondria and glycemic control in
vivo, C57bl/6 mice were subjected to chronic infusion of
AngII by means of an osmotic pump, combined with the
pharmacological blockade of AT1R by CS-866 or of AT2R
by PD-123319. We compared the effect on the four groups:
control (vehicle implanted), AngII infusion, AngII infusion
with AT1R blockade, and AngII infusion with AT2R block-
ade. In the AngII-treated groups, glucose levels after the
glucose challenge were signiﬁcantly higher than in
the control (33% elevation in area under the curve of the
glucose level, n  18, P  0.01; Fig. 4A), and the AngII-
induced change in glycemic control was signiﬁcantly sup-
pressed by blockade of either AT1R or AT2R (13% or 17%
suppression, n  18, P  0.05 and 0.01, respectively; Fig.
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FIG. 3. Overexpression of AT2R in C2C12 cells augments AngII-
induced reduction in mitochondrial biogenesis. Angiotensin II recep-
tors (AT1R or AT2R) were overexpressed in C2C12 cells by CAG
promoter–driven expression vectors previous to the treatment with
AngII (10
6 mol/l) for 48 h (A–D). Mitochondrial DNA copy number
(mtDNA) estimated by quantitative PCR analysis in C2C12 cells
overexpressing AT1R (A) or AT2R (B)( n  12 per group). C: Western
blots of proteins that are related to mitochondrial biogenesis (PGC1
and Tfam). D: Densitometry of the Western blots. The density of the
blots for PGC-1 and Tfam was normalized by that for the internal
control (-actin) (n  8). The values were standardized to those for
the control. *P < 0.05, **P < 0.01 vs. control.
A
B
100
50
150
200 400
300
200
100
0 15 30 60 120
**
## #
AngII(day7)
Glucose tolerance test 
Vehicle
AngII+CS
AngII+PD
AngII (-)
+CS+PD
(+) day7 AngII (-)
+CS+PD
(+) day7
C D
Serum insulin 
3
2
1
0
Body weight 
30
20
10
0
40
0m 15m
*
AngII (-)
+CS+PD
(+) day7 (-)
+CS+PD
(+) day7 AngII (-)
+CS+PD
(+) day7 (-)
+CS+PD
(+) day7
pre post
Food intake
AngII (-)
+CS+PD
(+) day0 (-)
+CS+PD
(+) day7 AngII (-)
+CS+PD
(+) day0 (-)
+CS+PD
(+) day7 AngII (-)
+CS+PD
(+) AngII (-)
+CS+PD
(+)
Area under the curve
(% Vehicle) Blood glucose (mg/dl)
(ng/ml)
(g) (g/day)
3
2
1
0
4
FIG. 4. Exogenous administration of AngII in mice for 1 week provokes
glucose intolerance without changes in body weight or food intake. The
8-week-old male C57bl/6 mice were treated with a subpressor dose (0.1
g/g body wt/day) of AngII or PBS (vehicle) by means of a subcutane-
ously implanted osmotic pump. The AT1R blocker, CS-866 (CS), or the
AT2R blocker, PD-123319 (PD), was orally administered (A–D). A:
Blood glucose levels (mg/dl) at 0, 15, 30, 60, and 120 min after
intraperitoneal injection of 2.0 g/kg body wt glucose and area under the
curve of the glucose level (% vehicle) (n  18 per group). B: Serum
insulin levels during glucose tolerance test at 0 and 15 min (0m, 15m).
C: Body weight of mice before and 1 week after the implantation of
osmotic pumps (pre, post). D: Food intake of mice during the experi-
ment. *P < 0.05, **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. the
AngII-treated group.
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centrations at 0 and 15 m of the glucose challenge showed
a parallel increase with glucose levels (Fig. 4B). There
were no signiﬁcant changes in body weight or food intake
in any of the four groups (Fig. 4C and D).
AngII reduces mitochondrial content and increases
triglycerides in the skeletal muscle in both AT1R-
and AT2R-dependent manners. We then examined the
muscle triglyceride level in the quadriceps of the mice and
found that they were higher in the AngII group (78%
increase, n  8, P  0.01, Fig. 5A) than in the control
group. Pharmacological blockade of either AT1R or AT2R
caused a signiﬁcant reduction in the muscle triglyceride
level compared with that in the AngII group (26% or 28%
reduction, respectively, n  8, P  0.05, Fig. 5A). To
conﬁrm that lipids were accumulated in the intramyocel-
lular region, we performed Oil-red-O staining and found
that AngII infusion increased intramyocellular lipids, and
the increase was suppressed by blockade of either AT1R
or AT2R (Fig. 5B). We also found that the ceramide
content in the muscle was parallel to the triglyceride level
(data not shown). The copy number of muscle mitochon-
drial DNA was reduced in the AngII group, and this change
was also signiﬁcantly diminished by blockade of either
AT1R or AT2R (Fig. 5C). Furthermore, COX and -HAD
activities in the muscle, which represent electron trans-
port and -oxidative function of mitochondria, respec-
tively, were signiﬁcantly reduced in the AngII group, and
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FIG. 5. AngII reduces mitochondrial content and increases triglyceride (TG) content in the skeletal muscle in both AT1R- and AT2R-dependent
manners. A: Muscle triglyceride content (muscle triglyceride) measured in the quadriceps (n  8 per group). B: Histological analysis of
AngII-induced lipid accumulation in muscle by Oil-red-O staining. Neutral lipids were stained in red. Scale bar: 100 m. C: mtDNA of the
quadriceps estimated by quantitative PCR analysis (n  12). D: Enzyme activity in the muscle of the mitochondrial proteins, cytochrome C
oxidase (COX), and -hydroxyacyl-CoA dehydrogenase (-HAD) (n  12). E: The relationship between area under the curve of the glucose levels
in the glucose tolerance test and mtDNA, or between muscle triglyceride and mtDNA. Symbols were distinguished according to the treatment. F:
Oxygen consumption and fat oxidation analyzed by indirect calorimetry. *P < 0.05, **P < 0.01 vs. control; #P < 0.05 vs. the AngII-treated group.
(Please see http://diabetes.diabetesjournals.org/cgi/content/full/db08-0949 for a high-quality digital representation of this ﬁgure.)
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AT2R, in a manner that was parallel to the mitochondrial
content (Fig. 5D). These experiments also showed that
mtDNA correlated signiﬁcantly with the area under the
curve of the glucose tolerance test (R  0.285, n  72,
P  0.01) and muscle triglyceride (R  0.267, n  72,
P  0.05) in the quadriceps (Fig. 5E). Respiratory gas
analysis was used to estimate oxygen consumption and fat
oxidation. Although oxygen consumption measured over
24 h showed no signiﬁcant changes in the four groups (Fig.
5F), a dramatic decrease in fat oxidation was observed in
the AngII-infused group (69% at night and 70% during the
day, n  8, P  0.05, Fig. 5F), and this change was
abrogated by blockade of either AT1R or AT2R and to a
greater extent by the AT2R blockade (41% or 46%
recovery at night, respectively, n  8, P  0.05, Fig. 5F).
Blockade of AT2R but not AT1R in AngII-infused
mice reverses reduction in expression and protein
levels of molecules involved in mitochondrial bio-
genesis. Consistent with the result for C2C12 cells (Fig.
2D), AT2R blockade by PD-123319 in AngII-infused mice
reversed the reduction in the expression in PGC1 and
Tfam, but blockade of AT1R by CS-866 did not affect their
expressions (Fig. 6A). Western blot analysis and densitom-
etry of the blots conﬁrmed this result (Fig. 6B and C). On
the other hand, the AngII-induced reduction in mitochon-
drial proteins involved in electron transport or fatty acid
oxidation (ATP synthase [ATPsyn], COX, and medium-
chain fatty acyl-CoA dehydrogenase [MCAD]) were all
suppressed by blockade of either AT1R or AT2R (Fig. 6B
and C), and the manner of changes in the protein levels
was parallel to that seen in mtDNA (Fig. 5B).
These results indicate that the AngII-induced reduction
in muscle mitochondrial content in mice is caused by
AT2R-dependent suppression of mitochondrial biogenesis
and also by AT1R-dependent mechanisms that are not
directly related to their biogenesis.
Microarray analysis of the skeletal muscle of AngII-
infused mice. Detailed results of microarray analysis are
presented in the supplemental materials.
DISCUSSION
In the study reported here, we found that AngII reduced
mitochondrial content in cultured myotubular cells and
skeletal muscle of mice. In addition, the AngII-infused
mice showed a decrease in fat oxidation that was associ-
ated with an increase in intramuscular triglyceride content
and impaired glucose tolerance. These ﬁndings imply that
the cardiovascular hormone AngII, which has been
thought previously to act mainly on the cardiovascular
system, may have novel roles in the regulation of mito-
chondria and lipid metabolism in the skeletal muscle.
To determine the receptor responsible for the effects of
AngII on mitochondrial content, we used pharmacological
blockade and RNA interference of the receptors in C2C12
myotubes, which exhibited substantial expressions of
both AT1R and AT2R. We found that the decrease in
mitochondrial content induced by treatment with AngII for
48 h could be reversed by the pharmacological and genetic
blockades of AT2R but not by those of AT1R. Consistent
with this ﬁnding, AngII decreased the expression levels of
PGC1 and Tfam, which positively regulate mitochondrial
biogenesis, in an AT2R-dependent manner. We further
conﬁrmed that this reduction was attributable to AT2R but
not to AT1R, by means of overexpression of the receptors
in C2C12 cells. In the skeletal muscle of AngII-infused
mice, on the other hand, the pharmacological blockade of
either AT1R or AT2R partially but signiﬁcantly reversed
the AngII-induced reduction in mitochondrial content. The
change in muscle mitochondrial content was parallel to
the mitochondrial protein levels of ATPsyn, COX, and
MCAD and the enzyme activity of COX and -HAD. While
still in this in vivo situation, the AngII-induced decrease in
expression and protein levels of PGC1 and Tfam was
prevented by the pharmacological blockade of AT2R but
not by that of AT1R. Therefore, the difference in the
protein levels under the AT1R blockade was observed
between PGC1/Tfam and ATPsyn/COX/MCAD.
These results imply that the in vitro and in vivo regula-
tion of mitochondria by AngII was somewhat different
under the present experimental conditions. AngII reduced
mitochondrial content predominantly via an AT2R-depen-
dent direct suppression of mitochondrial biogenesis in the
cultured myocytes. On the other hand, mitochondrial
content in the skeletal muscle in mice appeared to be
determined by a complex combination of factors. Cyto-
kines and hormones released from other tissues, ROS
production, and nutritional availability are all known to
inﬂuence mitochondrial DNA copy number in vivo (25).
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FIG. 6. Blockade of AT2R but not AT1R in AngII-infused mice reverses
reduction in expression and protein levels of molecules involved in
mitochondrial biogenesis. A: Expression of genes involved in mitochon-
drial biogenesis in the skeletal muscle of the mice (n  12 per group).
B: Western blots of proteins that are related to mitochondrial biogen-
esis (PGC1 and Tfam), electron transport (ATPsyn and COX), and
-oxidation (MCAD). C: Densitometry of the Western blots. The
density of the blot was normalized by that for the internal control
(-actin) (n  8). The values were standardized to those for the
control. **P < 0.01 vs. control; #P < 0.05, ##P < 0.01 vs. the AngII-
treated group.
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hormone adiponectin from adipose tissue has been re-
ported to be decreased by AngII infusion via AT1R (26).
Because adiponectin has been shown to increase mito-
chondrial number (27), decreased adiponectin levels via
AT1R might affect mitochondria in the in vivo condition.
These kinds of mechanisms can explain the difference,
which we found in the present study, between the results
for AT1R blockade under the in vitro and in vivo experi-
mental conditions.
The ﬁnding that the expression and protein levels of
molecules involved in mitochondrial biogenesis in skeletal
muscle of AngII-infused mice were not modulated by
AT1R suggests that AT1R-dependent pathways reduce
mitochondrial content by a way other than via the reduc-
tion of mitochondrial biogenesis. Therefore, we propose
that mitochondrial degradation was involved in the regu-
lation of mitochondrial content in the present study.
Mitochondria are degraded in lysosomes by a process
known as “mitophagy” (28). Previous studies have shown
that AT1R-dependent pathways augment ROS production,
which is known to promote mitophagy and reduce mito-
chondrial content in rat kidney (29,30). Moreover, in our
experiments, an AT1R-dependent increase in lysosomes
has been observed in AngII-treated C2C12 cells (data not
shown). These ﬁndings together suggest that the AngII-
induced ROS production via AT1R would augment muscle
mitophagy and that an AT1R blockade can be expected to
protect muscle mitochondria from various insults that lead
to mitophagy.
Chronic AngII infusion in rodents has been shown to
reduce glucose uptake in muscle and provoke insulin
resistance (31). Consistent with this ﬁnding, our study
demonstrated that 1-week exogenous administration of a
subpressor dose of AngII with a subcutaneously implanted
osmotic pump exacerbated glycemic control in C57bl/6
mice without causing changes in food intake or suppres-
sion in insulin secretion. The AngII-induced glucose intol-
erance in mice was accompanied by a reduction in
mitochondrial content and an increase in triglyceride
levels in the skeletal muscle. Previous studies have shown
a strong relationship between accumulation of intramus-
cular triglycerides and insulin resistance (32,33). Although
triglycerides themselves are thought to be biologically
inactive, accumulating muscle triglyceride levels lead to
an increase in intramuscular fatty acids, which has been
shown to inhibit insulin signaling via phosphorylation of
serine residues in insulin receptor substrate 1 (34). Other
lipid metabolites, such as long-chain fatty acyl coenzyme
A, diacylglycerols, and ceramides, have also been shown
to impair muscle insulin signal directly (35).
Muscle triglycerides are believed to increase in associ-
ation with a reduction in fat oxidation; indeed, a signiﬁcant
relationship between reduced fat oxidation and increased
triglyceride levels has been demonstrated by means of
percutaneous biopsy of the vastus lateralis muscle in
insulin-resistant subjects (36). Moreover, reduced muscle
mitochondrial content has been shown to correlate with
decreased fat oxidation and insulin resistance in nondia-
betic subjects with a family history of type 2 diabetes (37).
The fact that PGC1-dependent pathways shift fuel sub-
strates for oxidation from carbohydrates to lipids, in
addition to promoting mitochondrial biogenesis, can ex-
plain the relationship between mitochondrial content and
fat oxidation in muscle (38). These studies point to the
importance of mitochondrial content in skeletal muscle as
an upstream element in the pathogenesis of intramuscular
lipids and insulin resistance.
The ﬁndings in the present study lead us to hypothesize
that administration of AngII in mice causes glucose intol-
erance at least partly by reducing the mitochondrial con-
tent in skeletal muscle, which results in reduced fat
oxidation and subsequent accumulation of intramuscular
lipids. In support of this notion, we identiﬁed signiﬁcant
relationships among mitochondrial content in quadriceps
on the one hand, and intramuscular triglyceride and the
index of glucose intolerance, expressed as area under
the curve of glucose levels after glucose challenge, on the
other. The results of the in vivo energy expenditure, which
showed that the AngII infusion in mice did not change the
oxygen consumption, indicate that the reduction in muscle
mitochondrial content by AngII was not mediated through
changes in chronic physical activity. However, it is possi-
ble that AngII ﬁrst impairs glycemic control and sub-
sequently reduces mitochondrial content, because
hyperglycemia itself has been known to decrease mito-
chondrial content (39,40). Future studies should speciﬁ-
cally focus on the time course of the AngII-induced
decrease in mitochondrial content and deterioration of
glycemic control, as well as their causal relationship.
To summarize, we have demonstrated that AngII causes
a reduction in mitochondrial content in cultured myotu-
bular cells and the skeletal muscle in mice. Exogenous
administration of AngII with an osmotic pump in mice
provoked glucose intolerance, which is associated with
reduced mitochondrial content, decreased fat oxidation,
and increased intramuscular triglyceride levels. Putting
these ﬁndings together suggests that the cardiovascular
hormone AngII, which has been thought to act mainly on
the cardiovascular system, can also regulate mitochon-
drial content and lipid metabolism in the skeletal muscle,
and thus affect glycemic control. AngII-infused mice are
likely to reduce muscle mitochondrial content through
both AT1R and AT2R by different mechanisms: through
AT1R-dependent augmentation of mitochondrial degradation
and AT2R-dependent direct suppression of their biogenesis.
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